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Abstract
In five prospectively diagnosed patients with relapsing post-herpes simplex encephalitis (HSE),
NMDAR-antibodies were identified. Antibody synthesis started 1–4 weeks post-HSE, preceding
the neurological relapse. Three of five patients improved post-immunotherapy, one spontaneously,
and one has started to improve. Two additional patients with NMDAR-antibodies, 9 with
unknown neuronal surface-antibodies, and one with NMDAR and unknown antibodies were
identified during retrospective assessment of 34 HSE-patients; the frequency of autoantibodies
increased over time (serum p=0.004, CSF p=0.04). The three retrospectively identified NMDAR-
antibody positive patients also had evidence of relapsing post-HSE. Overall, these findings
indicate that HSE triggers NMDAR-antibodies and potentially other brain autoimmunity.
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Introduction
Relapsing post-herpes-simplex-virus encephalitis (post-HSE) is a potentially lethal
complication that occurs in 13–24% of the patients as a result of viral reactivation or
suspected immunological mechanisms.1–3 In the latter, patients frequently develop
choreoathetosis, symptoms do not respond to acyclovir, and the HSV polymerase chain
reaction (HSV-PCR) in cerebrospinal fluid (CSF) is negative.1–4 These findings and the
observation that some patients (11%) with HSE develop N-methyl-D-aspartate receptor
(NMDAR) IgG antibodies,5 led us to postulate that these antibodies could be involved in
neurological relapses,4 a hypothesis supported by a few case reports.4,6–8 In the current
study we provide a robust link between NMDAR antibodies and relapsing post-HSE by
demonstrating novel NMDAR-antibody synthesis during the weeks that lapse between HSE
and the development of new symptoms. We also show that HSE is a robust trigger of cell-
surface/synaptic autoimmunity not limited to NMDAR. These findings are important
because they assist in establishing the correct diagnoses and direct appropriate treatment
approaches.
Patients and Methods
From June 2012 until May 2013, serum and CSF of 5 patients seen by the authors with
relapsing post-HSE were studied at Hospital Clinic and August Pi i Sunyer Biomedical
Research Institute (IDIBAPS), University of Barcelona. In addition, 34 patients with definite
or probable HSE were included to determine the frequency of neuronal antibodies after HSE
(Supplementary Table 1). From these 34 patients, archived serum and/or CSF obtained 1–88
days after HSE were available for study. Information was retrospectively provided by
investigators of the California Encephalitis Project (Supplementary methods “Identification
of patients”). All patients were examined for antibodies to cell-surface/synaptic antigens
(Supplementary methods “list of antibodies tested, and techniques”).9–12 The appearance of
antibodies over time was assessed using the Mann-Whitney U test (IBM SPSS Version 20).
Studies were approved by the internal review board of Hospital Clinic-IDIBAPS. Partial
data on two patients (Case #2 and #5) were previously reported;4,6 in this report we
demonstrate NMDAR-antibody seroconversion post-HSE of Case #2.
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The five patients prospectively identified included 4 children (median age 7 months, range
2–28; two female) and a 24 year-old man (Table 1). Detailed information and videos are
provided in Supplementary material; the timing of initial antibody synthesis and symptoms
is outlined in Figure 1. Overall, relapsing or new neurological symptoms started 7–41 days
(median 24) after onset of HSE. In four patients the symptoms occurred after having
improved from HSE, and in one (case #1) the symptoms (choreic-like movements)
developed in contiguity seven days after hospital admission for HSE. In the four children,
choreoathetosis was the most prominent finding (Supplementary Video); other symptoms
included irritability, sleep disorder, and unresponsiveness. The adult patient developed
abnormal behavior and personality change. CSF showed pleocytosis in 4/5 patients, with a
white blood cell count (WBC) similar to that of the viral phase (HSE: median 49 WBC/μl,
range 6–120; relapse: median 69 WBC/μl, range 10–153). Brain MRI did not show new T2/
FLAIR signal abnormalities in three patients; patient#5 had a mild interval increase of a
fronto-temporal T2/FLAIR abnormality without new necrotic lesions, and one patient did
not have follow-up MRI.
All patients were treated for relapsing symptoms with a second 15–21-day course of
intravenous acyclovir and four received immunotherapy (Table 1). Immunotherapy was not
used in patient #1 who improved spontaneously (Supplementary video). Within four weeks
of relapsing symptoms, only patient #5 improved with steroids; the other three did not
respond to steroids and IVIg and were subsequently treated with rituximab (375mg/kg,
weekly, four weeks) and cyclophosphamide (monthly IV pulses, first dose: 500 mg/m2,
second and subsequent doses: 750 mg/m2). At the last follow-up, two patients have returned
to the pre-relapse level (case#2, 24-month follow-up, case#3, 7-month follow-up), and the
patient with the shortest follow-up (case #4, 4-month follow-up) has started to improve.
Serum and CSF samples of all five patients were available from the time of symptom relapse
and in four from the time of HSE. None of the patients had NMDAR antibodies during HSE
but all had high antibody titers, both in CSF and serum, 3–5 weeks later by the time of
relapsing symptoms (Figure 1). All five patients had IgG and IgM NMDAR antibodies, and
two had mild IgA antibody reactivity (Supplementary Table 2). All patients’ serum/CSF
reacted with the GluN1 subunit of the NMDAR but not with the subunit mutated at amino
acid 368, as reported in anti-NMDAR encephalitis (Supplementary material).15 Antibodies
to the other indicated antigens were not identified.
Retrospective cases
Among the 34 patients with HSE whose archived serum/CSF samples were retrospectively
studied, 17 had the samples obtained during the first week of the infection, 10 afterwards,
and 7 during the first week and afterwards (Supplementary Table 1). Twelve of 34 patients
had antibodies against neuronal cell-surface antigens, two of them against NMDAR, 9
against unknown antigens, and one both. In those two patients with only NMDAR
antibodies (cases #6 and 7 in Supplementary Table 3, and vignette, case #7), the serum/CSF
samples had been obtained after the first week of HSE (74 and 61 days). In case #8, CSF
from the first week of HSE was available and showed extensive neuropil/cells-surface
staining without NMDAR antibodies, suggesting an early presence of antibodies to
uncharacterized antigens (Figure 2); however, NMDAR antibodies were identified on day
42 indicating seroconversion after the first week. For all three patients the antibody isotype
was IgG (two also had IgM) against the GluN1 subunit of the receptor (Figure 2,
Supplementary Table 2). In the three patients the reason for serum/CSF analysis was “new
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onset or worsening neurological symptoms”. The antibodies of the other 9 patients (4
detected during the first week of HSE and 5 afterwards) were directed against cell-surface
antigens of unknown identity (one representative case shown in Figure 2).
Cell surface autoantibodies were identified in 1/17 sera and 5/22 CSF during the first week
of HSE and in 5/13 sera and 7/12 CSF afterwards (Figure 2D). The frequency of
autoantibodies increased over time in both serum and CSF (serum p=0.004, CSF p=0.04,
Supplementary figure 1) suggesting that HSE triggers brain autoimmunity.
Discussion
This study shows that “relapsing post-HSE” is often anti-NMDAR encephalitis, that this
immune response underlies different complications (e.g., choreoathetosis in children,
abnormal behavior in adults), which may occur in contiguity or a few weeks after HSE, and
that HSE is a trigger of cell-surface/synaptic autoimmunity.
The involvement of immune mechanisms in HSE has been previously suggested by the
observation that immunocompetent patients have a more severe disease course than
immunocompromised patients,16 the beneficial effect of combining steroids with
acyclovir,17,18 and the recent identification of NMDAR antibodies in some patients with
HSE.4–6,8 We report here eight patients with relapsing post-HSE related to NMDAR
antibodies, five of them with serum/CSF samples available from both the episode of HSE
and the episode of neurological relapse. In these five patients (4 prospectively studied) the
synthesis of NMDAR antibodies started shortly after HSE preceding the neurological
relapse, providing a robust link between these entities. Altogether, 4/8 patients were children
and all developed “choreoathetosis”. In contrast, behavior, personality and memory deficits
were the main symptoms in adults with only one (case #7) presenting abnormal movements.
These differences regarding symptom presentation according to age are in line with those
reported in non HSE-related anti-NMDAR encephalitis.4,19
Patient #1 (two months old), the youngest patient we know with NMDAR antibodies,
developed choreic-like movements seven days after diagnosis of HSE. The awareness of one
of the authors of “choreoathetosis post-HSE” led to antibody testing on day one of
admission (without detection of NMDAR antibodies), and on day 24, which demonstrated
NMDAR antibodies in serum and CSF. Subsequently, the patient improved spontaneously
with a decrease of antibodies in CSF. The seroconversion demonstrated in this patient and in
the other four prospectively identified cases, together with the detection of antibodies to
cell-surface antigens in more than half of the patients tested after one week of HSE suggest
that this infection often triggers brain autoimmunity which may fade spontaneously (e.g.,
case #1) or lead to progressive neurological symptoms.
Whether a mechanism of molecular mimicry or the release of antigens by viral neuronal
lysis and inflammation leads to synaptic autoimmunity is unknown. We favor the second
mechanism for three reasons; First, the broad immune response of some patients, mostly
against unknown autoantigens, suggests release of multiple potential autoantigens; Second,
the description of similar neurological complications in other viral encephalitis, such as
Japanese B encephalitis, which may associate with a bimodal clinical course, including
choreoathetosis and behavioral changes (to our knowledge, cell-surface autoimmunity has
not been examined in these cases),20 and third, the identification of other viruses such as
Epstein-Barr or cytomegalovirus in the CSF of some patients with anti-NMDAR
encephalitis, further supporting a non-specific viral-induced immunological mechanism
(unpublished observations).
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Findings from this study have several practical implications: 1) patients with prolonged,
worsening or relapsing symptoms post-HSE should be tested for NMDAR and other
antibodies to cell-surface/synaptic antigens, 2) identification of these immune responses is
important because NMDAR-related symptoms are potentially responsive to immunotherapy,
and 3) immunotherapy appears to be safe in patients with relapsing post-HSE. Future studies
should determine prospectively the frequency of brain autoimmunity in patients with HSE,
identify those who progress to develop post-HSE symptoms, characterize the unknown
antigens, and further assess the effects of immunotherapy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Clinical course, treatment, and CSF/serum NMDAR antibody titers in four patients
with neurological relapses post-HSE
Scaling of X-axes is different in all patients reflecting length of follow-up. Broken x-axis
represents discontinuous axis and change of tick interval. Right y-axis and grey curve:
quantitative measure of disease severity Pediatric Cerebral Performance Category,
PCPC14(1=normal,2=mild disability, 3=moderate disability, 4=severe disability, 5= coma or
vegetative state, 6=dead). Left y-axis: filled boxes NMDAR antibody titer in CSF, empty
diamonds NMDAR antibody titer in serum (multiplied x100 to fit the same axis as CSF).
Camera symbol represent available video segments in the supplementary video. IVIg:
intravenous immunoglobulins, IvMP: intravenous methylprednisolone, or steroids: oral
steroids, Ritux: rituximab, CycP: cyclophosphamide.
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Figure 2. Determination and frequency of antibodies to NMDAR and uncharacterized cell-
surface antigens in a retrospective cohort of patients with HSE
A: HEK cells expressing GluN1/GluN2 subunits of the NMDAR incubated with CSF of the
indicated patients (left column, green fluorescence), and a monoclonal antibody to GluN1
(middle column, red); the merged immunostaining is shown in the right column. Nuclei of
neurons demonstrated with DAPI. Scale bar 10μm. Note that only patient #7 had antibodies
to NMDAR (a similar staining was obtained with cells transfected only with GluN1, not
shown). B and C: Reactivity of the CSF of the same patients with sagittal sections of rat
brain (B), and live rat hippocampal neurons (C). The CSF of patient #7 shows a typical
pattern of NMDAR reactivity with the neuropil of hippocampus as well as with the cell-
surface of neurons; the CSF of patient #8 shows reactivity with a neuropil antigen expressed
on the cell-surface of neurons (the identity of the antigen is unknown), and the CSF of
patient #37 was negative in both tests. Scale bar in B 500μm; Scale bar in C 10μm.
D: Percentage of patients’ serum and CSF samples harboring IgG antibodies to NMDAR
(black) or to other neuronal cell-surface antigens (grey) during and after the first week of
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HSE; the identity of other neuronal antigens was unknown. Frequency increased over time
(serum p=0.004, CSF p=0.04, Mann Whitney U test).
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